Vesicular Galectin-3 levels decrease with donor age and contribute to the reduced osteo-inductive potential of human plasma derived extracellular vesicles

Aging

Volumn 8, Issue 1, 2016, Pages 16-33

  Weilner, Sylvia ^a,b   Keider, Verena ^a   Winter, Melanie ^a   Harreither, Eva ^a   Salzer, Benjamin ^a   Weiss, Florian ^a   Schraml, Elisabeth ^a   Messner, Paul ^a   Pietschmann, Peter ^c   Hildner, Florian ^e,f   Gabriel, Christian ^d,e,f   Redl, Heinz ^e,f   Grillari Voglauer, Regina ^a,b   Grillari, Johannes ^a,b,f  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^b Evercyte GmbH   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Red Cross Blood Transfusion Service of Upper Austria   (Austria)

^e LUDWIG BOLTZMANN INSTITUTE FOR EXPERIMENTAL AND CLINICAL TRAUMATOLOGY   (Austria)

^f Austrian Cluster for Tissue Regeneration   (Austria)

Author keywords

Aging; Bone; Extracellular vesicles; Galectin 3; Osteogenic differentiation

Indexed keywords

CELL PENETRATING PEPTIDE; GALECTIN 3; GALECTIN-3, HUMAN;

ADULT; AGE; AGING; BLOOD; BONE DEVELOPMENT; CELL AGING; CELL CULTURE; COMPARATIVE STUDY; DOWN REGULATION; DRUG EFFECTS; EXOSOME; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; MUTATION; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TIME FACTOR; UMBILICAL VEIN ENDOTHELIAL CELL; YOUNG ADULT;

ADULT; AGE FACTORS; AGING; CELL AGING; CELL-PENETRATING PEPTIDES; CELLS, CULTURED; DOWN-REGULATION; EXTRACELLULAR VESICLES; FEMALE; GALECTIN 3; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MUTAGENESIS, SITE-DIRECTED; MUTATION; OSTEOGENESIS; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; YOUNG ADULT;

EID: 84986626342     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100865     Document Type: Article

References (69)

1. Kozhevnikova MN, Mikaelian AS, Starostin VI: Molecular and genetic regulation of osteogenic differentiation of mesenchymal stromal cells. Izv Akad Nauk Ser Biol 2008:261-271.
2. Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, O'Brien CA, Bellido T, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC: Skeletal involution by ageassociated oxidative stress and its acceleration by loss of sex steroids. The Journal of biological chemistry 2007, 282:27285-27297.
3. Kassem M, Marie PJ: Senescence-associated intrinsic mechanisms of osteoblast dysfunctions. Aging Cell 2011, 10:191-197.
4. Roholl PJ, Blauw E, Zurcher C, Dormans JA, Theuns HM: Evidence for a diminished maturation of preosteoblasts into osteoblasts during aging in rats: an ultrastructural analysis. J Bone Miner Res 1994, 9:355-366.
5. Föger-Samwald U, Patsch JM, Schamall D, Alaghebandan A, Deutschmann J, Salem S, Mousavi M, Pietschmann P: Molecular evidence of osteoblast dysfunction in elderly men with osteoporotic hip fractures. Experimental gerontology 2014, 57C:114-121.
6. Bennett CN, Ouyang H, Ma YL, Zeng Q, Gerin I, Sousa KM, Lane TF, Krishnan V, Hankenson KD, MacDougald OA: Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 2007, 22:1924-1932.
7. Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA: Regulation of osteoblastogenesis and bone mass by Wnt10b. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:3324-3329.
8. Stevens JR, Miranda-Carboni GA, Singer MA, Brugger SM, Lyons KM, Lane TF: Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. Journal of Bone and Mineral Research 2010, 25:2138-2147.
9. Verkaar F, Zaman GJR: A model for signaling specificity of Wnt/Frizzled combinations through co-receptor recruitment. FEBS Letters 2010, 584:3850-3854.
10. Gordon MD, Nusse R: Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. The Journal of biological chemistry 2006, 281:22429-33.
11. Baht GS, Silkstone D, Vi L, Nadesan P, Amani Y, Whetstone H, Wei Q, Alman BA: Exposure to a youthful circulaton rejuvenates bone repair through modulation of β-catenin. Nature communications 2015, 6:7131.
12. Fais S, Logozzi M, Lugini L, Federici C, Azzarito T, Zarovni N, Chiesi A: Exosomes: The ideal nanovectors for biodelivery. Biological Chemistry 2013:1-15.
13. Nolte'T Hoen ENM, Buermans HPJ, Waasdorp M, Stoorvogel W, Wauben MHM, 'T Hoen PAC: Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. Nucleic Acids Research 2012, 40:9272-9285.
14. Weilner S, Schraml E, Redl H, Grillari-Voglauer R, Grillari J: Secretion of microvesicular miRNAs in cellular and organismal aging. Exp Gerontol 2013; 48:626-633.
15. Fevrier B, Raposo G: Exosomes: Endosomal-derived vesicles shipping extracellular messages. Current Opinion in Cell Biology 2004:415-421.
16. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
17. Chen X, Liang H, Zhang J, Zen K, Zhang CY: Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell 2012, 3:28-37.
18. Mathivanan S, Ji H, Simpson RJ: Exosomes: extracellular organelles important in intercellular communication. J Proteomics 2010, 73:1907-1920.
19. Mathivanan S, Lim JW, Tauro BJ, Ji H, Moritz RL, Simpson RJ: Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol Cell Proteomics 2010, 9:197-208.
20. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, Ratajczak MZ: Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005, 113:752-760.
21. Müller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, Zieseniss S, Zahler S, Preissner K, Engelmann B: Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2003, 17:476-478.
22. Weilner S, Skalicky S, Salzer B, Keider V, Wagner M, Hildner F, Gabriel C, Dovjak P, Pietschmann P, Grillari-Voglauer R, Grillari J, Hackl M: Differentially circulating miRNAs after recent osteoporotic fractures can influence osteogenic differentiation. Bone 2015, 79:43-51.
23. van Niel G, Porto-Carreiro I, Simoes S, Raposo G: Exosomes: a common pathway for a specialized function. J Biochem 2006, 140:13-21.
24. Simpson RJ, Jensen SS, Lim JW: Proteomic profiling of exosomes: current perspectives. Proteomics 2008, 8:4083-4099.
25. Dumic J, Dabelic S, Flogel M: Galectin-3: An open-ended story. Biochimica et Biophysica Acta-General Subjects 2006:616-635.
26. Byrd JC, Mazurek N, Bresalier RS: Post-Translational Modification of Galectin-3 and Its Role in Biological Function. In Galectins and Disease Implications for Targeted Therapeutics. Volume 1115. American Chemical Society; 2012:137-151 SE-8. [ACS Symposium Series]
27. Wolbank S, Stadler G, Peterbauer A, Gillich A, Karbiener M, Streubel B, Wieser M, Katinger H, van Griensven M, Redl H, Gabriel C, Grillari J, Grillari-Voglauer R: Telomerase immortalized human amnion-and adipose-derived mesenchymal stem cells: maintenance of differentiation and immunomodulatory characteristics. Tissue Eng Part A 2009, 15:1843-1854.
28. Frankel AD, Pabo CO: Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55:1189-1193.
29. Keerthikumar, S., Chisanga, D., Ariyaratne, D., Al Saffar, H., Anand, S., Zhao, K., Samuel, M., Pathan, M., Jois, M., Chilamkurti, N., Gangoda, L. and Mathivanan, S. ExoCarta: A web-based compendium of exosomal cargo. Journal of Molecular Biology. 2015; doi: 10.1016/j.jmb.2015.09.019.
30. Théry C, Boussac M, Véron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S: Proteomic analysis of dendritic cellderived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. Journal of immunology (Baltimore, Md: 1950) 2001, 166:7309-7318.
31. Shimura T, Takenaka Y, Fukumori T, Tsutsumi S, Okada K, Hogan V, Kikuchi A, Kuwano H, Raz A: Implication of galectin-3 in Wnt signaling. Cancer Res 2005, 65:3535-3537.
32. Lepperdinger G: Inflammation and mesenchymal stem cell aging. Current Opinion in Immunology 2011:518-524.
33. Caplan AI: Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. Journal of Cellular Physiology 2007:341-347.
34. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O: Treatment of severe acute graftversus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
35. Otsuru S, Gordon PL, Shimono K, Jethva R, Marino R, Phillips CL, Hofmann TJ, Veronesi E, Dominici M, Iwamoto M, Horwitz EM: Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood 2012, 120:1933-1941.
36. Okamoto R, Watanabe M: Molecular and clinical basis for the regeneration of human gastrointestinal epithelia. Journal of gastroenterology 2004, 39:1-6.
37. Zhou S, Greenberger JS, Epperly MW, Goff JP, Adler C, Leboff MS, Glowacki J: Age-related intrinsic changes in human bonemarrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging cell 2008, 7:335-343.
38. Carlson BM, Faulkner JA: Muscle transplantation between young and old rats: age of host determines recovery. The American journal of physiology 1989, 256:C1262-C1266.
39. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA: Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005, 433:760-764.
40. Katsimpardi L, Litterman NK, Schein PA, Miller CM, Loffredo FS, Wojtkiewicz GR, Chen JW, Lee RT, Wagers AJ, Rubin LL: Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science (New York, NY) 2014, 344:630-4.
41. Kaiser J: Aging. "Rejuvenation factor" in blood turns back the clock in old mice. Science (New York, NY) 2014, 344:570-1.
42. Sinha I, Sinha-Hikim AP, Wagers AJ, Sinha-Hikim I: Testosterone is essential for skeletal muscle growth in aged mice in a heterochronic parabiosis model. Cell and tissue research 2014; 357:815-821
43. Carlson ME, Conboy IM: Loss of stem cell regenerative capacity within aged niches. Aging Cell 2007, 6:371-382.
44. Wilson S, Thorp BH: Estrogen and cancellous bone loss in the fowl. Calcif Tissue Int 1998, 62:506-511.
45. Corpas E, Harman SM, Blackman MR: Human growth hormone and human aging. Endocr Rev 1993, 14:20-39.
46. Gallo A, Tandon M, Alevizos I, Illei GG: The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PloS one 2012, 7:e30679.
47. Kiwaki K, Novak CM, Hsu DK, Liu FT, Levine JA: Galectin-3 stimulates preadipocyte proliferation and is up-regulated in growing adipose tissue. Obesity (Silver Spring) 2007, 15:32-39.
48. Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD, Milovanovic MZ, Nikolic IG, Zdravkovic NS, Djukic AL, Arsenijevic NN, Lukic ML: Galectin-3 deficiency accelerates high-fat dietinduced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes 2013, 62:1932-1944.
49. Pang J, Rhodes DH, Pini M, Akasheh RT, Castellanos KJ, Cabay RJ, Cooper D, Perretti M, Fantuzzi G: Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice. PLoS One 2013, 8:e57915.
50. Li Y-JJ, Kukita A, Teramachi J, Nagata K, Wu Z, Akamine A, Kukita T: A possible suppressive role of galectin-3 in upregulated osteoclastogenesis accompanying adjuvant-induced arthritis in rats. Lab Invest 2009, 89:26-37.
51. Aubin JE, Gupta AK, Bhargava U, Turksen K: Expression and regulation of galectin 3 in rat osteoblastic cells. J Cell Physiol 1996, 169:468-480.
52. Stock M, Schafer H, Stricker S, Gross G, Mundlos S, Otto F: Expression of galectin-3 in skeletal tissues is controlled by Runx2. J Biol Chem 2003, 278:17360-17367.
53. Tünnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F, Cardoso MC: Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2006, 20:1775-1784.
54. Blocki A, Wang Y, Koch M, Peh P, Beyer S, Law P, Hui J, Raghunath M: Not All MSCs Can Act as Pericytes: Functional In Vitro Assays to Distinguish Pericytes from Other Mesenchymal Stem Cells in Angiogenesis. Stem Cells Dev 2013, 22:2347-2355.
55. Shi S, Gronthos S: Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J Bone Miner Res 2003, 18:696-704.
56. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badylak S, Buhring HJ, Giacobino JP, Lazzari L, Huard J, Peault B: A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008, 3:301-313.
57. Inohara H, Segawa T, Miyauchi A, Yoshii T, Nakahara S, Raz A, Maeda M, Miyoshi E, Kinoshita N, Yoshida H, Furukawa M, Takenaka Y, Takamura Y, Ito Y, Taniguchi N: Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun 2008, 376:605-610.
58. Sakaki M, Oka N, Nakanishi R, Yamaguchi K, Fukumori T, Kanayama HO: Serum level of galectin-3 in human bladder cancer. J Med Invest 2008, 55:127-132.
59. Saussez S, Glinoer D, Chantrain G, Pattou F, Carnaille B, Andre S, Gabius HJ, Laurent G: Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 2008, 18:705-712.
60. Vereecken P, Awada A, Suciu S, Castro G, Morandini R, Litynska A, Lienard D, Ezzedine K, Ghanem G, Heenen M: Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res 2009, 19:316-320.
61. Vereecken P, Heenen M: Serum galectin-3 in advanced melanoma patients: a hypothesis on a possible role in melanoma progression and inflammation. J Int Med Res 2006, 34:119-120.
62. Xie L, Ni WK, Chen XD, Xiao MB, Chen BY, He S, Lu CH, Li XY, Jiang F, Ni RZ: The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol 2012, 138:1035-1043.
63. Yu LG: Circulating galectin-3 in the bloodstream: An emerging promoter of cancer metastasis. World J Gastrointest Oncol 2010, 2:177-180.
64. Esmailiejah AA, Taheriazam A, Golbakhsh MR, Jamshidi M, Shakeri M, Yahaghi E, Moghtadaei M: Analysis of serum levels and tissue expression of galectin-1 and galectin-3 as noninvasive biomarkers in osteosarcoma patients. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2015; Epub ahead of print.
65. Koca SS, Akbas F, Ozgen M, Yolbas S, Ilhan N, Gundogdu B, Isik A: Serum galectin-3 level in systemic sclerosis. Clin Rheumatol 2014; 33:215-220
66. Ten Oever J, Giamarellos-Bourboulis EJ, van de Veerdonk FL, Stelma FF, Simon A, Janssen M, Johnson M, Pachot A, Kullberg BJ, Joosten LA, Netea MG: Circulating galectin-3 in infections and non-infectious inflammatory diseases. Eur J Clin Microbiol Infect Dis 2013; 32:1605-1610.
67. Wang X, Zhang S, Lin F, Chu W, Yue S: Elevated Galectin-3 Levels in the Serum of Patients With Alzheimer's Disease. Am J Alzheimers Dis Other Demen 2015; 30:729-732.
68. Jin QH, Lou YF, Li TL, Chen HH, Liu Q, He XJ: Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus. Chin Med J (Engl) 2013, 126:2109-2115.
69. Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB, Chao CL, Wang SS, Hsein YC, Liao LC, Ho YL, Chen MF: The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009, 409:96-99.